Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Common Equity (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Common Equity for 14 consecutive years, with $24.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 3.35% year-over-year to $24.2 million, compared with a TTM value of $24.2 million through Sep 2025, down 3.35%, and an annual FY2024 reading of $23.5 million, up 10.81% over the prior year.
  • Common Equity was $24.2 million for Q3 2025 at Sunshine Biopharma, down from $25.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $41.9 million in Q2 2022 and bottomed at -$1.2 million in Q3 2021.
  • Average Common Equity over 5 years is $19.4 million, with a median of $22.7 million recorded in 2025.
  • The sharpest move saw Common Equity tumbled 111.57% in 2021, then skyrocketed 10117.97% in 2022.
  • Year by year, Common Equity stood at $211662.0 in 2021, then surged by 10117.97% to $21.6 million in 2022, then fell by 1.94% to $21.2 million in 2023, then grew by 10.81% to $23.5 million in 2024, then grew by 2.97% to $24.2 million in 2025.
  • Business Quant data shows Common Equity for SBFM at $24.2 million in Q3 2025, $25.7 million in Q2 2025, and $22.7 million in Q1 2025.